<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055379</url>
  </required_header>
  <id_info>
    <org_study_id>12962A</org_study_id>
    <secondary_id>2009-011144-19</secondary_id>
    <nct_id>NCT01055379</nct_id>
  </id_info>
  <brief_title>Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn</brief_title>
  <acronym>ACCORDO</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled Study to Evaluate if Rasagiline Can Improve Depressive Symptoms and Cognitive Function in Non-demented, Idiopathic Parkinson's Disease Patients: ACCORDO Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lundbeck Italia S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lundbeck Italia S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary endpoint for this study is the clinical response after 12 weeks of treatment,&#xD;
      defined as a change in total score from baseline depressive symptoms as measured by the Beck&#xD;
      Depression Inventory-Amended (BDI-IA) total score.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ACCORDO is a multicentre, randomised, double-blind, and placebo-controlled study conducted in&#xD;
      12 Italian centres. Subjects are screened by means of the BDI-IA (cut-off 15) and randomised&#xD;
      to treatment with rasagiline or placebo for 12 weeks.&#xD;
&#xD;
      Subjects have to be on stable treatment with dopaminergic agents at least 4 weeks before&#xD;
      baseline, and maintained so during the course of the study.&#xD;
&#xD;
      The primary objective is to evaluate whether rasagiline compared to placebo improves&#xD;
      depressive symptoms as evaluated by the BDI-IA total score.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in BDI-IA total score</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate if rasagiline compared to placebo improves cognitive function, over a treatment period of 12 weeks in idiopathic Parkinson´s Disease, using a formal neuropsychiatric cognitive test battery; quality of life (PDQ 39); apathy; ADL, motor function</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life using the PDQ-39 scale</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in apathy using the Apathy Scale</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ADL and motor function using UPDRS scales part II and III, respectively</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Depressive Symptoms</condition>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Rasagiline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline</intervention_name>
    <description>1 mg/day for 12 weeks; orally</description>
    <arm_group_label>Rasagiline</arm_group_label>
    <other_name>Azilect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily for 12 weeks; orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatient, male or female aged &gt;=40 and &lt;80 years. The subject has a diagnosis of&#xD;
             idiopathic Parkinson's Disease (PD) according to the United Kingdom Parkinson's&#xD;
             Disease Society brain bank diagnostic criteria for PD for the clinical diagnosis of&#xD;
             PD.&#xD;
&#xD;
          -  Depressive symptoms with a minimum severity of &gt;=15 using the BDI-IA.&#xD;
&#xD;
          -  Hoehn and Yahr stage I-III.&#xD;
&#xD;
          -  Under stable (4 weeks prior to baseline) dopaminergic treatment without significant&#xD;
             motor complication such as &quot;on-off&quot; phenomena and/or dyskinesia.&#xD;
&#xD;
          -  The subject and/or legal representative and/or impartial witness is/are able to read&#xD;
             and understand the Subject Information Sheet.&#xD;
&#xD;
          -  The subject and/or legal representative has/have signed the Informed Consent Form&#xD;
             (ICF) and if relevant the impartial witness has co-signed the ICF.&#xD;
&#xD;
          -  If female, must: agree not to try to become pregnant during the study (female patients&#xD;
             of childbearing potential will take pregnancy test, using a urine stick), AND use&#xD;
             adequate contraception (adequate contraception is defined as oral/systemic&#xD;
             contraception, intrauterine device, diaphragm in combination with spermicidal, or&#xD;
             condom for male partner in combination with spermicidal), OR have been menopausal for&#xD;
             at least 24 months prior to baseline, (OR) have been surgically sterilised prior to&#xD;
             baseline, OR have had a hysterectomy prior to baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A subject, who meets one or more of the following criteria at the Baseline Visit, is not&#xD;
        eligible for inclusion in this study:&#xD;
&#xD;
          -  Motor complications such as wearing off and on-off phenomena.&#xD;
&#xD;
          -  Mini-Mental State Examination (MMSE) &lt;26, corrected score.&#xD;
&#xD;
          -  Diagnosis of current or history of major depressive episode according to DSM-IV-TR®&#xD;
             criteria within 1 year before recruitment into the study.&#xD;
&#xD;
          -  Presence of any other neurodegenerative disorder other than PD, based on judgement of&#xD;
             investigator.&#xD;
&#xD;
          -  Psychotic symptoms, e.g. hallucination and delirium (determined by clinical&#xD;
             evaluation).&#xD;
&#xD;
          -  Presence of any unstable or untreated systemic disorder such as diabetes, cardiac&#xD;
             failure, or renal failure.&#xD;
&#xD;
          -  Use of any prohibited concomitant medication according to the timelines provided in&#xD;
             Appendix II.&#xD;
&#xD;
          -  Patient who have undergone Deep Brain Stimulation surgery.&#xD;
&#xD;
          -  Current treatment with antidepressants or history of treatment with antidepressants&#xD;
             less than 1 month prior to randomisation.&#xD;
&#xD;
          -  Current treatment or history of treatment less than 1 month prior to randomisation,&#xD;
             with antipsychotics, cholinesterase inhibitors, memantine, amantadine, or&#xD;
             anticholinergics.&#xD;
&#xD;
          -  Current treatment with selegiline or history of treatment with selegiline less than 90&#xD;
             days prior to randomisation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IT010</name>
      <address>
        <city>Cagliari</city>
        <zip>9134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT007</name>
      <address>
        <city>Chieti</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT004</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT005</name>
      <address>
        <city>Lido di Camaiore</city>
        <zip>55043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT003</name>
      <address>
        <city>Messina</city>
        <zip>98122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT012</name>
      <address>
        <city>Milano</city>
        <zip>20135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT001</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT011</name>
      <address>
        <city>Roma</city>
        <zip>161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT008</name>
      <address>
        <city>Rome</city>
        <zip>133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT015</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT013</name>
      <address>
        <city>Venezia</city>
        <zip>30126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IT009</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 22, 2010</study_first_submitted>
  <study_first_submitted_qc>January 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2010</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rasagiline</keyword>
  <keyword>Depressive Symptoms</keyword>
  <keyword>Cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_id>2009-011144-19</doc_id>
      <doc_type>EMA EudraCT Results</doc_type>
      <doc_url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011144-19/results</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

